Could selenium boost kidney cancer treatment?
NCT ID NCT02535533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tested a combination of two drugs—axitinib (a standard kidney cancer drug) and seleniomethionine (a form of selenium)—in 45 adults with advanced clear cell renal cell carcinoma that had spread. The goal was to find the safest dose and see if the combination could shrink tumors. Participants took seleniomethionine alone for two weeks, then added axitinib. The study focused on side effects and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- axitinib and seleniomethionine
- What this could lead to
- If it works, this combination could offer a new treatment option for advanced kidney cancer that has stopped responding to other therapies.
- What could go wrong
- This was an early-phase trial with only 45 participants, so results may not apply to all patients. The main goal was safety, not proof of effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States